The IncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling

Peng Han, Jing-wen Li, Bo-miao Zhang, Jia-chen Lv, Yong-min Li, Xin-yue Gu, Zhi-wei Yu, Yun-he Jia, Xue-feng Bai, Li Li, Yan-long Liu and Bin-bin Cui*

Abstract

Background: With more than 600,000 mortalities each year, colorectal cancer (CRC) is the third most commonly diagnosed type of cancer worldwide. Recently, mechanisms involving noncoding RNAs have been implicated in the development of CRC.

Methods: We examined expression levels of IncRNA CRNDE and miR-181a-5p in 64 cases of CRC tissues and cell lines by qRT-PCR. Gain-of-function and loss-of-function assays were performed to examine the effect of CRNDE and miR-181a-5p on proliferation and chemoresistance of CRC cells. Using fluorescence reporter and western blot assays, we also explored the possible mechanisms of CRNDE in CRC cells.

Results: In this study, we found that the expression levels of the CRNDE were upregulated in CRC clinical tissue samples. We identified microRNA miR-181a-5p as an inhibitory target of CRNDE. Both CRNDE knockdown and miR-181a-5p overexpression in CRC cell lines led to inhibited cell proliferation and reduced chemoresistance. We also determined that β-catenin and TCF4 were inhibitory targets of miR-181a-5p, and that Wnt/β-catenin signaling was inhibited by both CRNDE knockdown and miR-181a-5p overexpression. Significantly, we found that the repression of cell proliferation, the reduction of chemoresistance, and the inhibition of Wnt/β-catenin signaling induced by CRNDE knockdown would require the increased expression of miR-181a-5p.

Conclusions: Our study demonstrated that the IncRNA CRNDE could regulate the progression and chemoresistance of CRC via modulating the expression levels of miR-181a-5p and the activity of Wnt/β-catenin signaling.

Keywords: CRNDE, miR-181a-5p, Wnt/β-catenin signaling, Colorectal cancer, Proliferation, Chemoresistance

Background

With more than 600,000 mortalities each year, colorectal cancer (CRC) is the third most commonly diagnosed type of cancer worldwide [1, 2]. Like many other cancer types, the development of CRC is a process characterized by multiple stages and involves accumulation of both genetic and epigenetic changes [3]. An extensive body of recent research has revealed that the initiation and progression of CRC are regulated by a number of cellular signaling pathways, including the TGFβ/SMAD pathway, the p53 pathway, the EGFR/MAPK pathway, the PI3K-Akt pathway, and the Wnt/β-catenin pathway [4]. Recently, mechanisms involving noncoding RNAs have also been implicated in the development of CRC [5–8].

Based on size, noncoding RNAs (ncRNAs) can be categorized into small ncRNAs (<200 nt) and long ncRNAs (>200 nt). Small ncRNAs, including microRNAs, have been demonstrated to function primarily via regulating gene expression, including modulating mRNA stability and repressing protein translation [9]. A number of...
microRNAs were found to act as oncogenes or tumor suppressor genes by previous reports [10–12]. Characterized by lack of cross species conservation [13, 14], the mechanism of action for long ncRNAs (lncRNAs) is poorly understood. However, rapidly accumulating evidence has consistently indicated that lncRNAs play essential roles in a variety of cellular processes, and therefore may contribute to the development of cancer and other human diseases [15, 16].

The lncRNA Colorectal Neoplasia Differentially Expressed (CRNDE) is transcribed from chromosome 16 on the strand opposite to the adjacent IRX5 gene [17]. The expression levels of CRNDE were originally found to be increased in CRC [17], and were also upregulated in a number of solid and hematopoietic cancer types, including liver [18], pancreatic [19], ovarian [20], kidney cancer [21], glioma [22], and leukemia [23]. Besides cancer progression, the CRNDE gene also participated in the regulation of neuronal differentiation, gametogenesis and other developmental processes [24]. In addition, the mouse ortholog of CRNDE was demonstrated to be involved in the maintenance of cellular pluripotency [25]. Although there was some preliminary evidence that CRNDE could interact with chromatin-modifying complexes to affect epigenetic regulation of gene expression [26], the mechanism by which CRNDE plays its role, particularly in the development of CRC, has not yet been elucidated.

In the present study, we found that the expression levels of the lncRNA CRNDE were upregulated in CRC clinical tissue samples. We identified microRNA miR-181a-5p as a target for CRNDE. Knockdown of CRNDE and overexpression of miR-181a-5p in CRC cell lines both led to inhibited cell proliferation and reduced chemoresistance. We also determined that β-catenin and TCF4 were inhibitory targets of miR-181a-5p, and that Wnt/β-catenin signaling was inhibited by both CRNDE knockdown and miR-181a-5p overexpression. Significantly, we found that the repression of cell proliferation, the reduction of chemoresistance, and the inhibition of Wnt/β-catenin signaling in CRC cells induced by CRNDE knockdown all required the activity of miR-181a-5p. Taken together, our study demonstrated that the lncRNA CRNDE could regulate the progression and chemoresistance of CRC via modulating the expression levels of miR-181a-5p and the activity of the Wnt/β-catenin signaling pathway.

**Methods**

**Clinical samples**

The procedures of this study were approved by the Institutional Review Board of Harbin Medical University. Written informed consent was obtained from 64 participants. Fresh colorectal cancer tissues and paired adjacent normal specimens were collected by surgical resection. The patients with colorectal cancer had received neither chemotherapy nor radiotherapy prior to section. Pathological diagnostics for colorectal cancer were determined by three pathologists. The clinical characteristics in 64 CRC patients is presented in the Table 1.

**TCGA analysis**

The RNA-seq data of 157 tumor and 30 matched normal samples were downloaded from The Cancer Genome Atlas (TCGA) Data Portal (https://tcga-data.nci.nih.gov/tcga/). The expression of IncRNAs was quantified by the customized data analysis pipeline that including the steps of quality control, alignment, and expression quantification. We utilized UCSC hg19 as the Homo sapiens reference genome and gene model for read mapping and quantification. The correlation analysis was performed based on Pearson product-moment correlation coefficient.

**Cell culture and treatment**

Human CRC cell lines HCT116 and SW480 were cultured in Dulbecco’s Modified Eagle Medium with 4.5 g/L glucose (DMEM; Gibco BRL, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS; Gibco BRL).

**Table 1** Correlation between CRNDE expression and clinical characteristics of CRC

| Factor                | Number | CRNDE expression (Low) | CRNDE expression (High) | P     |
|-----------------------|--------|------------------------|-------------------------|-------|
| Age (y)               |        |                        |                         |       |
| <60                   | 23     | 15                     | 8                       |       |
| ≥60                   | 41     | 17                     | 24                      |       |
| Gender                |        |                        |                         |       |
| Male                  | 39     | 16                     | 23                      |       |
| Female                | 25     | 16                     | 9                       |       |
| Tumor location        |        |                        |                         |       |
| Colon                 | 31     | 14                     | 17                      |       |
| Rectum                | 33     | 18                     | 15                      |       |
| Tumor size (cm)       |        |                        |                         |       |
| < 5                   | 29     | 21                     | 8                       |       |
| ≥ 5                   | 35     | 11                     | 24                      |       |
| Histologic grade      |        |                        |                         |       |
| Grade 1 + 2           | 51     | 31                     | 20                      |       |
| Grade 3 + 4           | 13     | 1                      | 12                      |       |
| Lymph node metastasis |        |                        |                         |       |
| Yes                   | 37     | 13                     | 24                      |       |
| No                    | 27     | 19                     | 8                       |       |
| Distant metastasis    |        |                        |                         |       |
| M0                    | 52     | 27                     | 25                      |       |
| M1                    | 12     | 5                      | 7                       |       |

*P < 0.05, **P < 0.01
and 1% antibiotic/antimycotic solution. Cells were maintained at 37 °C in an atmosphere of 5% CO₂ and 95% room air.

LncRNA CRNDE siRNA, control siRNA, miR-181a-5p and miR-181a-5p inhibitor were all obtained from GenePharma (Shanghai, China). 5-fluorouracil (5-Fu) and oxaliplatin (Oxa) were all purchased from Sigma Aldrich (St Louis, MO, USA). Lipofectamine™ 3000 (Life Technologies, San Diego, CA, USA) was used for cell transfection according to manufacturer's instructions. After 48 h of transfection, cells were treated different concentration of 5-Fu (0, 3, 6, 12, 24 and 48 μg/ml) or Oxa (0, 4, 8, 16, 32 and 64 μg/ml).

qRT-PCR
Total RNA was extracted from colorectal cancer cell lines and patient specimens using TRIzol reagent (Life Technologies) according to the manufacturer’s manual. One microgram of total RNA was used as template for cDNA synthesis using a PrimeScript RT Reagent Kit with cDNA Eraser (Takara Biotech, Dalian, China) and qRT-PCR was performed using SYBR Premix Ex Taq (Takara Biotech). MiRNA expression were performed in triplicate using SYBR PrimeScriptTM miRNA RT-PCR Kit (Takara Biotech). All qRT-PCR assays was performed on an ABI 7900 system (Applied Biosystems, Foster City, CA, USA). Expression levels of genes or miRNA were normalized to those of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or SNORD6 (U6 snRNA). 2^ΔΔCt method was applied for calculation of relative levels of genes and miRNA expression.

RNA fluorescence in-situ hybridization (FISH)
RNA FISH assays were performed to observe CRNDE location. CRC cells were fixed by 4% formaldehyde for 10 min at room temperature and then permeabilized using 0.5% Triton X-100 for 30 min. Afterwards, the cells were washed 3 × for 5 min in PBS and then Hybridized with cDNA probe labeled fluorochromes Cy3 (green).

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
MTT assay was used for cell proliferation and cell inhibition rate analysis. Colorectal cancer cells were seeded in 96-well plate at a density of 1 × 10^3 cells per well. After treatment, the cells were washed twice with phosphate buffer saline (PBS). Then, 10 μL of MTT dye (5 mg/mL) was added to the wells at different time points. After 4 h incubation, 100 μL of dimethyl sulfoxide (DMSO) was added to each well to dissolve the formazan crystals and the absorbance was measured at 590 nm.

Colony formation assay
HCT116 and SW480 cells (0.5 × 10^3 cells per well) were seeded in a six-well plate and cultured for 10 days after treatment. Colonies were then fixed with 10% formaldehyde for 10 min and stained for 5 min with 0.5% crystal violet. Then the number of colonies was counted using ImageJ and images were taken under Olympus microscope (Tokyo, Japan).

Bromodeoxyuridine (BrdU) assay
Colorectal cancer cell proliferation was determined by BrdU assay using a BrdU kit (Abcam, Cambridge, MA, USA) according to the manufacturer's instructions. Cells were growing on cover slips and incubated with BrdU during DNA synthesis for 1 h followed by staining with an anti-BrdU antibody after treatment. Images were acquired using an Olympus camera under a microscope.

Establishment of 5-Fu resistant cells
5-Fu resistant colorectal cells were generated by continuous exposure to increasing concentrations of 5-Fu (from 5 to 30 μg/ml) with repeated subculture until fully resistant to 5-Fu. Cells were first cultured in growing medium with 5 μg/ml 5-Fu for two months and the concentration of 5-Fu increased 5 μg/ml every two months.

Luciferase assay
CRNDE wild type with potential miR-181a-5p binding sites or mutant of each sites were generated and fused to the luciferase reporter vector psi-CHECK-2 (Promega, Madison, WI, USA). The full-length wild-type (WT) 3′ untranslated region (UTR) containing the predicted miR-181a-5p targeting site, and mutant (MUT) 3′-UTR of β-catenin and TCF4 were amplified and cloned into the psi-CHECK-2 vector. HEK293T cells were placed on a 24-well plate and grew till 80% confluence. Cells were then co-transfected with luciferase plasmids and miR-181a-5p or control miRNA. After 48 h transfection, firefly and renilla luciferase activities were measured with a Dual-Luciferase Reporter Assay System (Promega).

Pull-down assays
Pull-down assays were performed as described previously [27]. Briefly, S1-CRNDE and S1-CRNDE mutant were generated, and cotransfected with or without miR-181a-5p inhibitor. After 48 h of transfection, cells were harvested and washed by PBS for two times, then cross-linked in 0.37% formaldehyde, incubated in ice-cold lysis buffer (150 mM NaCl, 10 mM Hepes, 3 mM MgCl₂, 10% glycerol, 1% NP-40, 2 mM DTT, 1 mM PMSE, 1 × protenase inhibitor (Sigma), 10 ul RNase inhibitor (Promega)). The cell lysate was precleaned in agarose beads (Santa Cruz Biotechnology) at 4 °C for 1 h, then incubated and rotated in streptavidin beads (Thermo Fisher
Scientific, San Jose, CA, USA) at 4 °C for 3 h. The streptavidin beads were collected, washed in elution buffer (50 mM Hepes, 5 mM EDTA, 100 mM NaCl, 1% SDS, 10 mM DTT). The beads were heated at 70 °C for 45 min. miR-181a-5p expression was examined by qRT-PCR.

**Western blot analysis**

Total proteins were prepared from colorectal cells using RIPA buffer (50 mm Tris-HCl, 150 mm NaCl, 1 mm EDTA, 0.1% SDS, 1% Triton X-100, 0.1% sodium deoxycholate) with proteinase inhibitor cocktail (Boster, Wuhan, China). The lysates were centrifuged at 12,000 rpm for 15 min at 4 °C and protein concentration was measured by BCA kit (Beyotime Biotechnology, Beijing, China). Equal quantities of protein were electrophoresed through a 10% sodium dodecyl sulfate/polyacrylamide gel and transferred to a nitrocellulose membranes (Millipore, Billerica, MA). The membranes were blocked and then incubated with β-catenin, TCF4, Cyclin D1, Axin2 and GAPDH (Santa Cruz Biotechnology) overnight at 4 °C. Subsequently, the membranes were incubated with a HRP-conjugated anti-mouse or -rabbit secondary antibody (Santa Cruz Biotechnology) at room temperature for 1 h. The protein bands were visualized using a chemiluminescence reagent (ECL) kit (Beyotime Biotechnology).

**Statistics**

The data are expressed as the mean ± standard error (SD) from at least three independent experiments. The differences between two groups were analyzed using Student’s t test or a one-way ANOVA when more than two groups were compared. Correlations between miRNA expression and its targets were analyzed by the Spearman's test. A value of $P < 0.05$ was considered statistically significant. All statistical analyses were performed using GraphPad software version 5.0 (GraphPad Software, CA, USA).

**Results**

**CRNDE expression is elevated in CRC tissue**

In order to investigate the relevance of lncRNA CRNDE in CRC development, we first sought to determine the levels of CRNDE expression form TCGA database. As shown in Fig. 1a, expression of CRNDE was significantly upregulated in CRC tissues ($P < 0.001$). We also compared gene expression data from the GSO/GDS4385 dataset. As shown in Fig. 1b, expression of CRNDE was significantly upregulated in CRC tissues ($P < 0.01$). We also compared gene expression data from the GSO/GDS4385 dataset. As shown in Fig. 1c, expression of CRNDE was significantly upregulated in CRC tissues ($P < 0.001$). We also compared gene expression data from the GSO/GDS4385 dataset. As shown in Fig. 1d, expression of CRNDE was significantly upregulated in CRC tissues ($P < 0.001$). We also compared gene expression data from the GSO/GDS4385 dataset. As shown in Fig. 1e, expression of CRNDE was significantly upregulated in CRC tissues ($P < 0.001$). We also compared gene expression data from the GSO/GDS4385 dataset. As shown in Fig. 1f, expression of CRNDE was significantly upregulated in CRC tissues ($P < 0.001$). We also compared gene expression data from the GSO/GDS4385 dataset. As shown in Fig. 1g, expression of CRNDE was significantly upregulated in CRC tissues ($P < 0.001$). We also compared gene expression data from the GSO/GDS4385 dataset. As shown in Fig. 1h, expression of CRNDE was significantly upregulated in CRC tissues ($P < 0.001$). We also compared gene expression data from the GSO/GDS4385 dataset. As shown in Fig. 1i, expression of CRNDE was significantly upregulated in CRC tissues ($P < 0.001$). We also compared gene expression data from the GSO/GDS4385 dataset. As shown in Fig. 1j, expression of CRNDE was significantly upregulated in CRC tissues ($P < 0.001$).

---

**Fig. 1 CRNDE expression is elevated in CRC tissue.** a Expression levels of CRNDE analyzed from data retrieved from the TCGA database in CRC patients ($P < 0.001$). b Expression levels of CRNDE analyzed from GSO/GDS4385 ($P < 0.01$). c Expression levels of CRNDE as determined by qRT-PCR in 64 clinical CRC samples compared to those in adjacent normal tissue samples ($P < 0.01$). d CRNDE expression in six CRC cell lines compared with normal colorectal tissue pool. *$P < 0.05$, **$P < 0.01$ and ***$P < 0.001$. e Kaplan-Meier analysis of the association between GRIM-19 expression and the survival in 64 clinical CRC patients. $P < 0.001$.
miR-181a-5p did not cause any change in the expression (Additional file 2a) or knockdown (Additional file 2b) of but not by mutant (Fig. 2g). Importantly, overexpression 181a-5p were significantly inhibited by wild type CRNDE (Fig. 2f), we found that the expression levels of miR- and mutant CRNDE expression in CRC cell lines of miR-181a-5p (Fig. 2e). We next increased wild type down cell lines, we observed elevated expression levels by qRT-PCR analysis (Fig. 2d). In both CRNDE knock- CRC cell lines, HCT116 and SW480 cells, by siRNA knocked down CRNDE expression in two independent miR-181a-5p was indeed a target of CRNDE, we first trend opposite to that of CRNDE. To examine whether 181a-5p could reduce was co-transfected with miR-181a-5p into HEK293T cells, respectively, and then luciferase assays were per- formed. As shown in Fig. 2b, miR-181a-5p could reduce wild type and mutant-2 CRNDE luciferase activity. But it can’t affect mutant-1 activity. The results indicated that miR-181a-5p binds transcript position (43–50) of CRNDE. In tissue samples from 64 clinical CRC patients, we determined that the expression levels of miR-181a-5p were significantly downregulated (Fig. 2c), a inhibitory regulation of miR-181a-5p by CRNDE was further corroborated by the analysis of clinical samples. We also observed inverse correlation between the expression levels of CRNDE and miR-181a-5p in CRC tis- sues (Fig. 2i, \( r = -0.632, P < 0.001 \)). Taken together, our data supported that miR-181a-5p was an inhibitory target of CRNDE in both CRC cells and tissue samples.

CRNDE promotes CRC cell proliferation and chemoresistance

To investigate the function of CRNDE on CRC cell proliferation, we first knocked down the expression of CRNDE in two CRC cell lines, HCT116 and SW480 cells. We then performed MTT cell proliferation assay on these cells. We found that knockdown of CRNDE in both cell lines significantly inhibited cell proliferation (Fig. 3a). Significantly, overexpression of miR-181a-5p in both HCT116 and SW480 cells was able to recapitulate the inhibitory effects on cell proliferation conferred by CRNDE knockdown (Fig. 3b). In contrast, CRNDE over-expression and miR-181a-5p knockdown both led to increased cell proliferation in CRC cells (Additional file 3a and b). We also performed additional assays to confirm the regulation of cell proliferation by CRNDE and miR-181a-5p. In crystal violet staining assay, colony formation of CRC cells was inhibited by knockdown of CRNDE (Fig. 3c) and by overexpression of miR-181a-5p (Fig. 3d). Consistently, we observed significantly less ac- tively divided cells in BrdU assay with CRNDE knock- down (Fig. 3e) and miR-181a-5p overexpression (Fig. 3f). These data collectively indicated that CRNDE promoted CRC cell proliferation.

As previous research demonstrated that noncoding RNAs are involved in the chemoresistance of cancer cells [28], we hypothesized that CRNDE and miR-181a-5p could also regulate the chemoresistance of CRC cells. To test this hypothesis, we treated CRNDE knockdown or miR-181a-5p overexpressing CRC cells with an increasing serial of concentrations of 5-Fu. As expected, 5-Fu led to cell growth inhibition in a dose-dependent manner. We found that CRNDE knockdown (Fig. 4a) and miR-181a-5p overexpression (Fig. 4b) appeared to increase the sensitivity of CRC cells to 5-Fu treatment and therefore further inhibited cell growth. Conversely, CRNDE overexpression (Additional file 4a) and miR-181a-5p knockdown
(Additional file 4b) resulted in decreased 5-Fu sensitivity, and partially alleviate the growth inhibition of CRC cells induced by 5-Fu treatment. These results were further confirmed by the treatment of another chemotherapy drug Oxa. Consistently, CRNDE knockdown (Fig. 4c) and miR-181a-5p overexpression (Fig. 4d) led to increased sensitivity of CRC cells to Oxa treatment, and CRNDE overexpression (Additional file 4c) and miR-181a-5p knockdown (Additional file 4d) led to decreased Oxa sensitivity of CRC cells. Importantly, we also found that in
chemoresistant CRC cells, the expression levels of CRNDE were significantly increased (Fig. 4e), while the expression levels of miR-181a-5p were decreased (Fig. 4f). Taken together, these data indicated that CRNDE increased the resistance of CRC cells against chemotherapy drugs.

**MiR-181a-5p targets β-catenin/TCF4 and inhibits Wnt/β-catenin signaling**

We next used publicly available algorithms (DIANA TOOLS and microRNA.org) to identify potential targets of miR-181a-5p. From TarBase v7.0 of DIANA TOOLS [29], we noticed that intracellular signal transducer β-catenin and transcriptional factor TCF4 in the Wnt/β-catenin signaling pathway were downregulated in human umbilical vein endothelial cells (HUVEC) after miR-181a-5p transfection (Fig. 5a). We then sought to confirm this prediction in the context of CRC cells. Based on the predicted binding sites of miR-181a-5p, we generated β-catenin and TCF4 3’-UTR wild type (WT) and mutant (MUT) luciferase reporter plasmids (Fig. 5b). We then performed luciferase reporter assays by co-transfeting luciferase reporter plasmids with miR-181a-5p. We found that the overexpression of miR-181a-5p decreased the luciferase activity driven by the wild type 3’-UTRs of both β-catenin and TCF4, but caused no change in the luciferase activity driven by the mutant 3’-UTRs of both β-catenin and TCF4 (Fig. 5c). In contrast, knockdown of miR-181a-5p increased the luciferase activity driven by the wild type 3’-UTRs of both β-catenin and TCF4, but not by the mutant 3’-UTRs of both β-catenin and TCF4 (Fig. 5c). In contrast, knockdown of miR-181a-5p increased the luciferase activity driven by the mutant 3’-UTRs of both β-catenin and TCF4 (Fig. 5c). In contrast, knockdown of miR-181a-5p increased the luciferase activity driven by the mutant 3’-UTRs of both β-catenin and TCF4 (Fig. 5c). In contrast, knockdown of miR-181a-5p increased the luciferase activity driven by the mutant 3’-UTRs of both β-catenin and TCF4 (Fig. 5c).

Furthermore, the protein levels of both β-catenin and TCF4 in CRC cells were reduced by miR-181a-5p overexpression (Fig. 5d), and were increased by miR-181a-5p knockdown (Additional file 5b). The inhibition of β-catenin and TCF4 by miR-181a-5p was also confirmed in clinical samples. In 64 CRC tissue samples, we were able to establish inverse correlation between the expression levels of miR-181a-5p and β-catenin ($r = -0.562, P < 0.001$), and between those of miR-181a-5p and TCF4 ($r = -0.518, P < 0.001$) (Fig. 5e). Since β-catenin and...
TCF4 are important components in the Wnt/β-catenin signaling pathway, we next sought to determine whether miR-181a-5p could affect the activity of Wnt/β-catenin signaling. With TOP/FOP luciferase activity assay, we found that overexpression of miR-181a-5p significantly inhibited the activity of Wnt/β-catenin signaling (Fig. 5f), and that knockdown of miR-181a-5p stimulated the activity of Wnt/β-catenin signaling (Additional file 5c). Finally, we found that the levels of downstream target genes of the Wnt/β-catenin signaling pathway, including Cyclin D1 and Axin2, were substantially decreased by miR-181a-5p overexpression in CRC cells (Fig. 5g).

CRNDE promotes CRC cell proliferation and chemoresistance via miR-181a-5p mediated regulation of Wnt/β-catenin signaling

Our previous results demonstrated that CRNDE knockdown and miR-181a-5p overexpression led to inhibition of CRC cell proliferation and chemoresistance. Since CRNDE inhibited miR-181a-5p expression, and miR-181a-5p inhibited Wnt/β-catenin signaling, it is possible that the inhibition of CRC cell proliferation and chemoresistance induced by CRNDE knockdown was due to increased miR-181a-5p expression and consequent inhibition of Wnt/β-catenin signaling. To test this
hypothesis, we knocked down β-catenin or TCF4, respectively, and performed MTT cell proliferation assays in the presence of 5-Fu or Oxa. As showed in Additional file 6, inhibition of Wnt/β-catenin signaling resulted in CRC cell chemoresistance. We next concomitantly knocked down the expression of miR-181a-5p in CRNDE knockdown CRC cells. Significantly, while CRNDE knockdown led to significantly inhibited CRC cell proliferation, simultaneous miR-181a-5p knockdown completely reversed the inhibition of cell proliferation (Fig. 6a), indicating that the increased levels of miR-181a-5p expression were essential for the cell proliferation inhibition induced by CRNDE knockdown. Consistently, miR-181a-5p knockdown also completely reversed the inhibition of colony formation of CRC cells caused by CRNDE knockdown (Fig. 6b). These phenotypes were not only observed in HCT116 cells, but also in SW480 cells (Additional file 7a and b). With regard to the regulation of CRC cell chemoresistance by CRNDE, we found that the increased sensitivity of CRC cells to both 5-Fu (Fig. 6c and Additional file 7c) and Oxa (Fig. 6d and Additional file 7d) treatment induced by CRNDE knockdown was completely abolished by simultaneous miR-181a-5p knockdown, indicating that the increased levels of miR-181a-5p expression were also essential for the increased sensitivity of CRC cells to

![Fig. 6 Regulation of CRC cell proliferation, chemoresistance and Wnt/β-catenin signaling by CRNDE requires miR-181a-5p.](image-url)

- **a** MTT cell proliferation assay, **b** colony formation assay, **c** MTT cell proliferation assay under the treatment of the indicated concentrations of 5-Fu or **d** Oxa, **e** The protein levels of β-catenin and TCF4 as determined by Western blot analysis, and **f** TOP/FOP luciferase activity assay performed in HCT116 cells transfected with siR-CRNDE or siR-control simultaneously with inhibitors of miR-181a-5p or miR-control. *P < 0.05
chemotherapy drugs induced by CRNDE knockdown. Importantly, we also sought to determine whether CRNDE regulated Wnt/β-catenin signaling in CRC cells, and whether this regulation was dependent on miR-181a-5p. As expected, knockdown of CRNDE led to decreased protein levels of both β-catenin and TCF4, presumably via upregulation of miR-181a-5p. However, simultaneous knockdown of miR-181a-5p was able to reverse the repression of β-catenin and TCF4 expression (Fig. 6e and Additional file 7e). In addition, CRNDE knockdown inhibited the activity of Wnt/β-catenin signaling, as evidenced by TOP/FOP luciferase activity, but this inhibition was abolished by simultaneous miR-181a-5p knockdown (Fig. 6f and Additional file 7f), suggesting that CRNDE regulated Wnt/β-catenin signaling in CRC cells via modulating the expression of miR-181a-5p. Collectively, these data strongly support the hypothesis that CRNDE regulated Wnt/β-catenin signaling via modulating the expression of miR-181a-5p (Fig. 7).

Discussion

In this study, we focused our research on the regulation of CRC progression and chemoresistance by the lncRNA CRNDE. We started our investigation by examining the expression levels of CRNDE in CRC clinical samples. We found significant increase in CRNDE expression in CRC samples, and this result was also corroborated by the analysis of available data in the TCGA database. In fact, CRNDE has been shown to be upregulated in numerous types of cancers [18–23], but the molecular mechanism of CRNDE in the regulation of cancer progression was not clear.

We identified miR-181a-5p as a target of CRNDE by bioinformatics prediction based on sequence complementarity. Changes in CRNDE expression led to corresponding changes in the expression levels of miR-181a-5p, but changes in miR-181a-5p expression did not affect the expression levels of CRNDE, suggesting that miR-181a-5p was downstream of CRNDE. The inverse correlation between the expression levels of CRNDE and miR-181a-5p in both clinical samples and the TCGA database further validated the target relation between the two non-coding RNAs. To study the functional roles of CRNDE and miR-181a-5p in regulating CRC progression and chemoresistance, we performed experiments in two independent CRC cell lines. This design would ensure that any result in our study would not be restricted to a single line of cells. We found that knockdown of CRNDE led to repressed cell proliferation and reduced chemoresistance, which was consistent with the oncogenic roles of CRNDE revealed by previous studies. Importantly, we also found that overexpression of miR-181a-5p induced the same phenotypes as CRNDE knockdown, which was once again consistent with the inhibitory regulation of miR-181a-5p by CRNDE.

The involvement of miR-181a-5p in cancer development has been studied by many groups, and the results were controversial. MiR-181a-5p was found to be up-regulated in pancreatic cancer and breast cancer [30, 31], and other miR-181 family members were up-regulated in hepatocellular cancer stem cells [32, 33]. However, other studies demonstrated that miR-181 was down-regulated in gliomas [34] and aggressive chronic lymphocytic leukemia [35]. Even in CRC development, miR-181a could function as both oncogene and tumor suppressor. MiR-181a was found to be associated with poor prognosis of colorectal cancer [36, 37]. MiR-181a also promoted tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1 [38]. In contrast, the expression levels of miR-181a were shown to increase during the progression from non-neoplasia to dysplasia in inflammatory bowel disease-associated CRC, whereas decrease when dysplasia develops into cancer [39]. Our study appears to support a tumor suppressor role for miR-181a-5p, in terms of cell proliferation and chemoresistance. The mechanism of action of miR-181a-5p was initially investigated via target prediction. We identified β-catenin and TCF4 as inhibitory targets of miR-181a-5p. This prediction was confirmed by multiple lines of evidence. First, miR-181a-5p was able to inhibit the wild type 3′-UTR activities of β-catenin and TCF4 in a luciferase assay, but had no effect in the same assay on the activities of the mutant 3′-UTR devoid of miR-181a-5p binding ability.
Second, miR-181a-5p overexpression reduced the expression of endogenous β-catenin and TCF4, and thereby inhibited the activity of Wnt/β-catenin signaling.

Although our study did not provide direct evidence whether the changes in Wnt/β-catenin signaling activity were required for the regulation of CRC cell proliferation and chemoresistance by CRNDE and miR-181a-5p, numerous previous studies have implicated Wnt/β-catenin signaling in the regulation of cell proliferation and chemoresistance (summarized in [40]). In this context, it is reasonable for us to conclude that CRNDE promotes CRC cell proliferation and chemoresistance via miR-181a-5p mediated regulation of Wnt/β-catenin signaling. From clinical characteristics analysis, high CRNDE leads to more Lymph node metastasis. Further investigation for CRNDE relative to CRC metastasis is needed.

Conclusions
In our investigation, we have established a signaling cascade involving CRNDE and miR-181a-5p in the regulation of Wnt/β-catenin signaling, cell proliferation and the chemoresistance of CRC cells. We postulated that if restoration of increased miR-181a-5p expression levels by a miRNA inhibitor could abolish the phenotypes induced by CRNDE knockdown, it would indicate that miR-181a-5p was required for CRNDE to regulate Wnt/β-catenin signaling, CRC cell proliferation and chemoresistance. Our study maybe provide an efficient therapeutic approach for CRC treatments.

Additional files

Additional file 1: Nuclear location of CRNDE in CRC cancer cells. RNA FISH assays were performed in HCT116 and SW480 cells for CRNDE expression. (TIF 2436 kb)

Additional file 2: Effects of miR-181a-5p on CRNDE expression. a Expression levels of miR-181a-5p as determined by qRT-PCR in HCT116 and SW480 cells transfected with miR-181a-5p or miR-control. b Expression levels of miR-181a-5p as determined by qRT-PCR in HCT116 and SW480 cells transfected with a microRNA inhibitor targeting miR-181a-5p (miR-181a-5p inhibitor) or a control microRNA inhibitor (miR-control inhibitor). c Expression levels of CRNDE as determined by qRT-PCR in HCT116 and SW480 cells transfected with miR-181a-5p or miR-control. d Expression levels of CRNDE as determined by qRT-PCR in HCT116 and SW480 cells transfected with a microRNA inhibitor targeting miR-181a-5p or miR-control inhibitor. **P < 0.01, ***P < 0.001. (TIF 2575 kb)

Additional file 3: CRNDE overexpression and miR-181a-5p knockdown promote CRC cell proliferation. a MTT cell proliferation assay performed in HCT116 and SW480 cells transfected with miR-181a-5p. b MTT cell proliferation assay performed in HCT116 and SW480 cells transfected with a microRNA inhibitor targeting miR-181a-5p or miR-control inhibitor. *P < 0.05. (TIF 1506 kb)

Additional file 4: CRNDE overexpression and miR-181a-5p knockdown promote CRC cell chemoresistance. a MTT cell proliferation assay performed in HCT116 and SW480 cells transfected with miR-181a-5p or miR-control inhibitor and treated with the indicated concentrations of 5-Fu. b MTT cell proliferation assay performed in HCT116 and SW480 cells transfected with miR-181a-5p inhibitor or miR-control inhibitor and treated with the indicated concentrations of 5-Fu. c MTT cell proliferation assay performed in HCT116 and SW480 cells transfected with plasmids overexpressing CRNDE or a control vector and treated with the indicated concentrations of Oxa. (TIF 2723 kb)

Additional file 5: Inhibition of miR-181a-5p promotes Wnt/β-catenin signaling. a Luciferase activity assay performed in HBE293 cells co-transfected with a microRNA inhibitor targeting miR-181a-5p and luciferase reporter plasmids driven by either WT or MUT 3′UTR of β-catenin and TCF4 that was devoid of miR-181a-5p binding activity. b The protein levels of β-catenin and TCF4 as determined by Western blot analysis in HCT116 and SW480 cells transfected with miR-181a-5p inhibitor or miR-control inhibitor. c TOP/FOP luciferase activity in HCT116 and SW480 cells transfected with a microRNA inhibitor targeting miR-181a-5p or a control microRNA inhibitor. *P < 0.05. (TIF 2515 kb)

Additional file 6: Wnt/β-catenin signaling is required for CRC cell chemoresistance. a β-catenin was silenced in HCT116 and SW480 cells. The protein levels of β-catenin as determined by Western blot analysis. b TCF4 was deleted in HCT116 and SW480 cells. The protein levels of TCF4 as determined by Western blot analysis. c MTT cell proliferation assay performed in β-catenin silencing HCT116 and SW480 cells treated with the indicated concentrations of 5-Fu. d MTT cell proliferation assay performed in TCF4 deletion HCT116 and SW480 cells treated with the indicated concentrations of 5-Fu. e MTT cell proliferation assay performed in TCF4 deletion HCT116 and SW480 cells treated with the indicated concentrations of Oxa. f MTT cell proliferation assay performed in CRC cells transfected with siRNA targeting CRNDE or siR-control simultaneously with miR-181a-5p or miR-control. *P < 0.05. (TIF 4563 kb)

Additional file 7: Regulation of CRC cell proliferation, chemoresistance and Wnt/β-catenin signaling by CRNDE requires miR-181a-5p. a MTT cell proliferation assay. b Colony formation assay. c MTT cell proliferation assay under the treatment of the indicated concentrations of 5-Fu or Oxa. d β-catenin and TCF4 protein levels as determined by Western blot analysis. e The protein levels of β-catenin and TCF4 as determined by Western blot analysis. f TOP/FOP luciferase activity assay performed in SW480 cells transfected with siRNA targeting CRNDE or siR-control simultaneously with miR-181a-5p or miR-control. *P < 0.05. (TIF 2723 kb)

Abbreviations

S-Fu: 5-Fluorouracil; CRC: Colorectal cancer; CRNDE: Colorectal neoplasia differentially expressed; HUVEC: Human umbilical vein endothelial cells; lncRNAs: Long noncoding RNAs; ncRNAs: Noncoding RNAs; Oxa: Oxaliplatin; TCGA: The cancer genome atlas; UTR: Untranslated region

Acknowledgements
None.

Funding
This study was supported by National Natural Science Foundation of China (81272704 and 81402367); Harbin Medical University Innovation Foundation for Scientific Research.

Availability of data and materials
The datasets supporting the findings of this study are included within the article.

Authors’ contributions
HP, JWL, BMZ, YML and XYG did the assays in vitro; HP, JW2, ZNY and YHJ performed experiments in vivo; XFB, LL and YLL collected clinical sample; HP, JW2, BMZ, XFB and BBC collected analyzed the data; HP and BBC wrote the manuscript; BBC designed this study. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.
Ethics approval and consent to participate
The procedures of this study were approved by the Institutional Review Board of Harbin Medical University.

Received: 6 July 2016 Accepted: 3 January 2017
Published online: 13 January 2017

References

1. Ferlay J, Shin HR, Soerjomataram I, Siegel RL, Lortet-Tieulent J, eds. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. IARC Press, Lyon, France. 2013.

2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

3. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut. 2011;60:116–29.

4. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489–99.

5. Kazemzadeh M, Safaralizadeh R, Feizt MA, Ravansabkhiz S, Solmi MH, Hashemzadeh S. The long noncoding RNA H19 is an oncogene in colorectal cancer. Cancer Biomark. 2016;16:499–505.

6. Saus E, Brunet-Vega A, Iraola-Guzman S, Pegueroles C, Gabaldon T, Pecaric L. Long non-coding RNAs as potential novel prognostic biomarkers in colorectal cancer. Front Genet. 2016;7:54.

7. Sun Z, Ou C, Ren W, Xie X, Li X, Li G. Downregulation of long non-coding RNA ANRIL suppresses lymphangiogenesis and lymphatic metastasis in colorectal cancer. Oncotarget. 2016.

8. Wang F, Ni H, Sun F, Li M, Chen L. Overexpression of IncRNA AFAP1-AS1 correlates with poor prognosis and promotes tumorigenesis in colorectal cancer. Biomed Pharmacother. 2016;81:152–9.

9. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Long non-coding RNAs, microRNA and cancer: many roads to maturity. Cell. 2012;150:1146–60.

10. Derrien T, Johnson R, Bussotti G, Iora L, Mikkelsen T, Nusbaum C, et al. The GENCODE v7 catalog of human gene structure. Genome Res. 2012;22:1775–89.

11. Pang KC, Frith MC, Mattick JS. Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. Trends Genet. 2006;22:1–5.

12. Wang RT, Xu M, Xu CX, Song ZG, Jin H. Decreased expression of miR216a predicts the prognostic outcome of the human hepatocellular carcinoma. Oncol Rep. 2014;31:2399–404.

13. Derrien T, Johnson R, Bussotti G, Iora L, Mikkelsen T, Nusbaum C, et al. The GENCODE v7 catalog of human gene structure. Genome Res. 2012;22:1775–89.

14. Pang KC, Frith MC, Mattick JS. Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. Trends Genet. 2006;22:1–5.

15. Tano K, Akimitsu N. Long non-coding RNAs in cancer progression. Front Genet. 2012;3:219.

16. Wiapinski O, Chiang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2012;21:354–61.

17. Grahame LD, Pedersen SK, Brown GS, Ho T, Kassir Z, Moinian AT, Viegtoh D, Dunne R, Pimlott L, Young GP, et al. Colorectal Neoplasia Differentially Expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas. Genes Cancer. 2011;2:829–40.

18. Chang Q, Chen J, Beezhold K, Castranova V, Shi X, Chen F. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer. 2012;11:58.

19. Ishikawa M, Yoshida K, Yamashita Y, Ota J, Takada S, Kisanuki H, Koinuma K, Hayashi M, Takekawa I, Mizushima T, Ikeda M, Sekimoto M, et al. The imprinted H19 IncRNA antagonizes let-7 microRNAs. Mol Cell. 2013;52:101–12.

20. Zaraite R, Boni V, Bandres E, Garcia-F oncillas J. miRNAs and lncRNAs: Could they be considered as biomarkers in colorectal cancer? Int J Mol Sci. 2012;13:840–65.

21. Vlachos IS, Paraskevopoulou MD, Karagioudi D, Georgakilas G, Vepouris T, Kanellos I, Anastasopoulous IL, Maniou S, Karathanou K, Kalfakakou D, et al. DAAAN-TarBase v7.0 indexing more than a half million experimentally supported miRNA:miRNA interactions. Nucleic Acids Res. 2015;43:D153–9.

22. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120:1046–54.

23. Wang Y, Yu Y, Tsuyada A, Ren X, Xu W, Stubbfeld K, Rankin-Gee BK, Wang SE. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene. 2011;30:1470–80.

24. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, et al. Identification of microRNA-181 by genome-wide screening identified as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009;50:472–80.

25. Meng F, Glaser SS, Francis H, DeMorrow S, Han Y, Passarini JD, Stokes A, Cleary JP, Liu X, Venter J, et al. Functional analysis of microRNA in human hepatocellular cancer stem cells. J Cell Mol Med. 2012;16:160–73.

26. Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z, You Y. Hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008;1236:185–93.

27. Zhu DX, Miao KR, Fang C, Fan L, Zhu W, Zhu HY, Zhang Y, Hong M, Li P, Xu W, Li JY. aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. Leuk Res. 2011;35:730–40.

28. Ishimura H, Honda R, Yamamoto H, Tanaka F, Shibata K, Mimori K, Takekawa I, Mizushima T, Ikeda M, Sekimoto M, et al. microRNA-181a is associated with poor prognosis of colorectal cancer. Oncol Rep. 2012;28:2221–5.

29. Pieler M, Winter E, Rass AL, Bauernhofer T, Gerger A, Kiesslich T, Lax S, Tannapfel A, Ullrich A, et al. The imprinted H19 IncRNA antagonizes let-7 microRNAs. Mol Cell. 2013;52:101–12.

30. Zaraite R, Boni V, Bandres E, Garcia-F oncillas J. miRNAs and lncRNAs: Could they be considered as biomarkers in colorectal cancer? Int J Mol Sci. 2012;13:840–65.